Cradle Genomics Announces $17 Million Series A

B2B Training: What’s the Most Effective Way of Learning?

B2B training, which is short for business-to-business training, is a popular and convenient type of training that enables entire companies to train their teams...

AlixPartners Forecasts: Household Products Could Cost U.S. Manufacturers and Consumers 15% More This Year Due to Resin Shortage

While companies can’t control the market forces at play, they can take action to mitigate the risk and impact of supply chain disruption.

Cradle Genomics, inventors of a novel prenatal testing methodology, today announced the close of a highly successful Series A funding round of $17.1 million with select investors. Illumina Ventures and Section 32 led the investment round with participation from Alexandria Real Estate Equities, Sea Lane Ventures, Listwin Ventures, and Axon Ventures. The funding will be used to support clinical development, corporate infrastructure, CLIA lab operations and the launch of Cradle Genomics’ transformational product offerings for non-invasive prenatal testing (NIPT).

“Our mission at Cradle Genomics is to deliver genetic knowledge for life, with a vision of better outcomes for every pregnancy,” said Tristan Orpin, CEO of Cradle Genomics. “We’re dedicated to the transformation of NIPT by offering the most comprehensive fetal genetic analysis and pregnancy health screening solutions at the earliest stages of pregnancy.”

NIPT offerings that are presently available rely on the measurement of trace amounts of circulating cell-free fetal DNA in maternal serum. The relatively low fraction of fetal DNA in maternal blood limits the scope of fetal genetic analysis and the pregnancy stage when testing can be offered. Cradle Genomics’ proprietary assay increases the purity of fetal DNA, making testing as early as week 5 of a pregnancy possible, while delivering the most comprehensive content among all NIPT providers for increased clinical utility.

“We are excited to be supporting such an extraordinary team of entrepreneurs,” said Nick Naclerio of Illumina Ventures. “We believe that Cradle Genomics is well-positioned to transform non-invasive prenatal testing.”

Cell-free DNA testing is the fastest growing market in the history of molecular diagnostics and is currently used in a number of health care settings. Cradle Genomics plans to make transformational advancements in NIPT by leveraging their intellectual property and assay expertise, in combination with their extensive market experience in reproductive health. The team at Cradle Genomics are passionate about improving patient care and enabling global access to the best possible prenatal solutions.



Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.